Objective To undertake a survey of the world's clinical trial registries to provide current data on the number, nature, funding source and geographical distribution of pregnancy drug trials (PDT).
Introduction
Pregnant women, like other women, can suffer from a range of conditions that require either ongoing or acute treatment. 1 It has been estimated that 40-80% of pregnant women take at least one medication during their pregnancy, [2] [3] [4] [5] most frequently during the first trimester. 5, 6 Regrettably, the majority of medicines are administered in pregnancy 'off-label', 1, 7 and over 90% of clinically approved drugs lack appropriate information on efficacy, safety, teratogenicity and pharmacokinetics in pregnancy. 6, 8, 9 Of the 172 new medications approved by the Federal Drug Administration (FDA) from 2000 to 2010, teratogenicity was undetermined in 98%, and for 73% no data regarding risk in pregnancy were available. 10 A recent article reported that 83% of medications prescribed in a UK maternity hospital were given off-label. 7, 11, 12 Hence, many women are administered drugs in pregnancy without adequate evidence from clinical trials or post-marketing surveillance of safety or efficacy. On the other hand, pregnant women are being deprived of medications due to reluctance of clinicians to prescribe medications without adequate safety and efficacy information 13 or medications that are unlicensed for use in pregnancy. 7 In response to the growing recognition of the problem, various initiatives to encourage inclusion of pregnant women in clinical trials and improve pregnancy-related safety information have been instigated, [14] [15] [16] e.g. MEPREP; The Pregnancy Drug Registry; 'Treating for Two'. 9 The FDA's new pregnancy and lactation labelling system was recently introduced to provide clinicians with well-organised information on medication efficacy and safety in pregnancy and lactation. 17 However, a major hurdle remains-the lack of clinical trial activity in the areas of drug development, dosing and evaluation in pregnancy. 17 Multiple studies have highlighted the lack of data available to guide drug dosing in pregnancy, 18 with the most commonly cited reason for exclusion of pregnant women from drug trials being safety concerns, both for the mother and the fetus. 3 , 11 Shields and Lyerly reported that only 1% of industry-sponsored trials in the USA were specifically designed for pregnant women, and 98% of trials involving drug administration actively excluded them. 19 As pointed out by Fisk and Atun in 2008, the current pharmaceutic industry model fails to support a pipeline in pregnancy drug development, with almost no new obstetric drugs being tested, marketed or licensed over the past two decades. 20 This is despite the fact that maternal and perinatal conditions contribute significantly to global morbidity and mortality, 21 and that the potential market for safe and effective drugs for the treatment of the pregnant patient is significant. 22 Apart from the two studies cited above, there are no published systematic studies of drug trials in pregnancy and no data on funding sources, therapeutic areas or geographic activity. This study was undertaken to survey the world's clinical trial registries to ascertain the number, location, funding source and pharmacological area of interest of trials of medications in pregnancy from 2013 to 2014 to provide up-to-date data on which areas for improvement can be identified and policy decisions be based.
Methods

Search strategy and selection criteria
Clinical trial registries were identified from the WHO International Clinical trials registry platform (ICTRP), as well as Clinicaltrials.gov (a data provider to the WHO ICTRP). All registries met specific criteria for content, quality and validity, and met the requirements of the International Committee of Medical Journal Editors. The registries included in this study are listed in Table 1 . As each registry had a different structure and employed a different search platform, a variety of search strategies were employed to identify, screen and select eligible trials for inclusion. In the smaller databases (Cuban, Brazilian, Sri Lankan, Thai and African), trials were identified by reading the titles and description of all listed trials. Several of the larger databases (The Netherlands, Indian, Iranian) had limited search functions and also required individual inspection of all available trials. The ICTRN, Korean and US clinical trial databases were first filtered by searching for reproductive health/pregnancy trials before individual assessment of the results based on title and description. The Australasian, Canadian, German, Chinese, Japanese and European clinical trials registries did not have an appropriate filter for topic or area, but instead were screened to include studies that only recruited women, before assessment based on trial title and metadata.
The inclusion criteria for this study were clinical trials 'active' between 1 January 2013 and 31 December 2014, involving a pharmaceutical intervention in women pregnant with a fetus (i.e. after conception and prior to or during delivery) who were intending to continue the pregnancy. All trials which had any form of activity over this time were included; thus trials completed in early 2013 were included, as were those not yet recruiting in late 2014. For the purpose of this study a pharmaceutical intervention was defined as a substance given in a trial that would normally be formulated and managed by a research pharmacist, including certain supplements and vitamins. Traditional medicines were excluded from this review, as were medicines given without supervision by a trial pharmacy.
Data extraction and management
For all relevant trials, data were extracted and compiled into an EXCEL worksheet for individual inspection and analysis. As far as possible, the following data for each trial were recorded: title; start and end date; sponsor; funding organisation; funder type and location; location of recruitment; study URL; name and type/class of drug; phase of trial. The total number of available trials on each database was recorded, as well as the total number of pregnancyrelated drug trials (Table 1) . Trials were then classified according to the following specific therapeutic areas (ordered by size): anaesthesia & analgesia (including anaesthetics and pain relief medications given during labour or surgical delivery, but not after delivery); preterm labour/ birth, including tocolytics and myometrial relaxants (PTB); pre-eclampsia & pregnancy-induced hypertension (PIH); gestational diabetes (GDM; both treatment and prevention); induction agents; anti-infectives (including antibiotics, antivirals and anti-fungals); miscarriage & recurrent pregnancy loss; dietary supplementation to improve pregnancy outcomes; fetal health & development (where the primary trial focus was on improving neonatal outcomes); hormonal disorders (including non-gestational diabetes); auto-immune disorders (primarily anti-phospholipid syndrome, but also including thyroid autoimmune disorders and immune response disorders); placental & amniotic complications (including oligohydramnios); intrauterine growth restriction (independent of pre-eclampsia); maternal disease (e.g. pre-existing medical conditions unrelated to pregnancy, not including those which could be characterised as endocrine or auto-immune); postpartum blood loss and haemorrhage (PPH) (including only trials in which medications were given prior to the birth of the baby); hyperemesis. Novel drugs were identified from the trial descriptions after confirming their absence from the Prescribing Medicines in Pregnancy Database (Australian Government Therapeutic Goods Association) and novel use was identified from the medication indication outlined in the full product information on both the TGA and FDA databases.
Data analysis
To analyse the data collectively in a global context, all relevant trials were combined, checked and filtered to exclude duplicates. Descriptive statistics were derived using Microsoft EXCEL on data from all registries individually, then on the combined data after pooling and cleaning. Initially, clinical trials were analysed on each registry separately to enable inter-registry comparison. The total number of trials on each database was compared, as well as the total relevant pregnancy trials, expressing as both a percentage and a raw number (Table 1 ). For the analysis by region, if a trial was sponsored/funded by separate entities in the same region, it was included only once in the region, but if the entities were in separate regions, then the trial was included in each separate region. Where possible (depending on the limitations of the search function of the registry) we compared the number of trials overall and the number of pregnancy-related drug trials both with and without filtering to include only those trials active over a 2-year period (2013) (2014) . To ensure data were current, only trials active in this period were included in the analysis of trials by therapeutic area and funder. 
Results
The number of trials in the registries varied between 165 and 193 645, with the percentage of pregnancy-related trials varying between 0% (0/573) and 7.4% (31/417) ( Table 1) . For the trials active in 2013 and 2014, the number of trials on the registries varied between 109 and 128 617, with the percentage of pregnancy-related drug trials (where possible to calculate) varying between 0% (0/ 306) and 6. 42% (7/109). The US registry (Clinicaltrials.-gov) was significant larger than the other databases, and was also the database with the largest number of pregnancy-related drug trials (515 in total; 189 active in 2013-2014); however, the percentage of pregnancy-related trials in this registry was only 0.27%, and 0.15% of 2013-2014 active trials. Interestingly, several of the smaller registries, such as those from Sri Lanka, Iran and India, contributed a significant number of the included pregnancy-related drug trials. As a proportion of the total number of trials on the individual registry, the African clinical trial database had the highest percentage of pregnancy-related drug trials (7.4% overall), followed by the Sri Lankan and the Iranian registries at 6.7% and 2%, respectively. The Cuban and Brazilian registries contained no pregnancy-based trials, and in the Korean, Canadian, Japanese and German registries, pregnancy drug trials comprised ≤0.3% of the trials. It should be noted that many of the trials in the smaller registries were initiated and funded from external countries, and a significant number of trials (16.7%) were included in more than one registry. Overall, of the total number of trials on all registries combined, just 0.48% investigated the administration of a therapeutic medication in pregnancy.
To ensure data were current, when we included only trials active from 2013-2014 (all databases combined), only 534 (0.32%) of the 168 826 trials active in this period were pregnancy drug trials. A regional analysis was then performed after filtering to exclude duplicate trials, separating the trials from all registries into regions based on geopolitical and/or socioeconomic characteristics (Table 2 , shown graphically in Figure S1 ); the data were analysed both by funder location and recruitment location to assess the prevalence of externally-funded studies ( Figure S2 ).
In general, the relative ranking of regions was the same, regardless of whether funder location or location of recruitment was analysed. However, a significant proportion of trials funded from the European and North American regions were carried out in developing regions such as India, South East Asia and Sub-Saharan Africa ( Figure S2 ). Of the European funded trials, 16/109 were carried out in areas of the developing world (14.7%), as were nine of the 76 North American-funded trials (11.8%). Despite the fact that the American registry had by far the largest number of total trials recorded overall (76.2% of all trials), it only contributed 14% of active pregnancy-related drug trials globally ( Figure S3 ). The region with the greatest number of pregnancy-related drug trials was North Africa/Middle East (110, of which 64 were Iranian studies) with 24% of all the active pregnancy drug-related trials identified; Europe was close behind at 21%.
The combined data (n = 455 trials) were then analysed to examine the level of trial activity across the different therapeutic areas. As shown in Figure 1 , the majority of trials focused on six main areas: anaesthesia & analgesia (85 trials), preterm birth and tocolysis (67), pre-eclampsia & PIH (49), gestational diabetes (44), labour induction & augmentation (40) and anti-infectives (39). Fewer than 5% of trials were focused on maternal disease, PPH and hyperemesis (data combined: seven, seven and five trials each, respectively). Interestingly, from a regional perspective, trials in the North American region had a greater focus on PTB and anti-infectives, whereas in Europe and SubSaharan Africa studies of anti-infectives predominated. Indian/SE Asian trials constituted almost half of all supplement trials, and North American trials almost half of all trials of maternal nutritional supplements. The North Africa & Middle East region contributed most trials in the auto-immune and PPH areas. Importantly, only 20 trials (4.4%) included a preplanned pharmacokinetic analysis (determination of plasma levels, elimination, etc.) of the trial medications. 
Analysis by therapeutic area
Each therapeutic area was evaluated in detail (Table S1 ).
A breakdown of individual studies in each therapeutic area revealed that in the anaesthestics/analgesia area (85 trials in total), analgesia during labor and prevention of intra-operative caesarean hypotension were the most common research topics. The preterm birth & tocolysis area had the second highest number of trials (67), with the focus mainly on prevention and acute management via tocolytics, with a large proportion of the trials exploring progesterone administration. Trials of preeclampsia & PIH (49) included a wide variety of medications, unlike many of the other therapeutic areas. Interestingly, many of these trials were based on drug administration early in pregnancy to prevent or control pre-eclampsia, rather than simply antihypertensive treatment alone.
In the GDM area, of the 44 trials included, half were studies of maternal dietary supplements as preventative therapies or treatment adjuncts, with the remaining half investigating the use of insulin and other oral hypoglycaemic agents. Trials investigating labour (40) centred mainly on methods of labour induction. Within the antiinfectives area (39), two main groups were prominent: HIV and malaria, with trials identified focusing on treatment, prevention, and prevention of transmission. Antibiotic prophylaxis during caesarean section was the next largest focus area in this category, although markedly less well represented. In the miscarriage & recurrent pregnancy loss area (24) , six trials investigated the benefits of progesterone administration, and the other 18 trials were spread across a variety of other medications (Table S1 ).
In the maternal nutritional supplement category (22) , approximately 50% of included trials were evaluating iron supplements in different formulations and routes of administration, with the remaining studies focusing on folic acid, calcium and vitamin D. In the fetal health & development area (19) , studies on antenatal steroid administration (for prevention of fetal respiratory complications) and supplementation for preventing neonatal morbidities were the most common research topics. The endocrine-related trials (18) focused on treatment of pre-existing diabetes and maternal thyroid conditions. In the auto-immune area (14) , studies focused primarily on conditions relating to maternal thyroid antibodies and antiphospholipid syndrome. Studies focused on treating the placenta were scarce (8), with no consistent pattern apparent in terms of indication or investigation drugs. Similarly, IUGR studies were also rare (7) and were dominated by studies on the effects of sildenafil administration to improve fetal growth and outcomes. With respect to PPH (7), all studies focused on drug trials to prevent post/intrapartum bleeding during caesarean section. There were remarkably few trials relating to treatment of maternal disease (7); four of these were concerned with antiplatelet disorders (specifically prevention of venous thromboembolism in patients with mechanical heart valves and/or those at higher risk of VTE). Few trials were carried out on treatment/prevention of hyperemesis (5); among them, several safety trials of previously discontinued medications were identified. Of all trials captured, the large majority were focused on pregnancy-related conditions, with only 66 (14%) applicable to maternal disorders outside of pregnancy. Interestingly, only one trial had a psychological outcome (depression) as its primary focus. 
Industry funding and drug development
A consistent, if predictable, observation arising from the analysis was that only a small number of trials investigated new drugs or therapeutic agents, with the vast majority of studies investigating new applications, formulations or administration regimes of an existing drug. Of the 455 trials identified for inclusion in this analysis, only three investigated novel drugs (0.66% of the total), all funded by the pharmaceutical industry. In total, across all studies and research areas, there were 32 trials funded by pharmaceutical companies, either in full or in part. This equates to just 7% of all included trials. Interestingly, the majority of these trials (12) were performed in Europe, with North America a close second (11) . None of the trials in Sub-Saharan Africa was pharma-funded, and in North Africa & Middle East only one trial was industry-funded; the remaining regions all had just two each. Of the pharma-funded trials identified, most (15) 
Trial activity comparisons with other areas of medicine
Finally, to put the extent of pregnancy-related drug trial activity in context and highlight disparities with other areas of medicine, we performed three sets of comparisons (Figure 2) . The first comparison was based on comparable healthcare costs, namely, breast cancer and preterm birth.
According to US data, preterm birth costs the country in excess of US$26 billion annually, with breast cancer costs broadly comparable at US$21 billion per year. 23, 24 Our analysis of all registries combined showed that only 67 pharmaceutical interventions had been studied in the area of preterm birth in the last 2 years. In comparison, accessing data from the five largest databases only, we identified 3022 trials studying pharmaceutical interventions in breast cancer (Figure 2A) , a 45-fold disparity. Secondly, a comparison was made based on comparable incidence: preeclampsia and lung cancer. According to Australian data, the incidence of pre-eclampsia is 42 in 100 000 in the total population, which is similar to the incidence of lung cancer, approximately 43 in 100 000. 25, 26 The total number of pre-eclampsia-focused drug trials active in the 2013-2014 period was 49, whereas drug trials of lung cancer were almost 50-fold more common at 2315 (again, only using the five largest databases) ( Figure 2B) . A further comparison based on incidence was also made with a non-malignant chronic disease, inflammatory bowel disease (IBD). IBD has an incidence in Australia of 29 per 100 000, less than the 42 in 100 000 incidence of pre-eclampsia. IBD had 567 active trials in the registries (2013-2014), 11-fold more common than pre-eclampsia, even though preeclampsia affects almost 1.5-fold more people in the community ( Figure 2C ). 26 
Discussion
Main findings
The present analysis of clinical trial registries was carried out to provide robust data on the number, location, funding source and therapeutic area of drug trials in pregnancy, to confirm or refute the prevailing view of the pregnant women as a 'drug orphan'. Our study confirms this widely held belief, showing that less than 0.5% of all registered clinical trials investigate pharmacological therapies in pregnancy. Importantly, the data highlight marked regional differences in the relative under-representation of pregnancy drug research, with the USA, German, Canadian, Japanese, Korean and Oceanic registries being particularly notable for their low representation of pregnancy drug trials. This likely reflects a combination of research culture, funder bias, perceived risk of litigation, and dominance of pharma-funding in these countries.
Although this study is, to the best of our knowledge, the first of its kind, the findings are consistent with several previous reports on the broad topic of clinical research in pregnancy. As pointed out recently by Ayad and Constantine, 17 pregnant women are actively excluded from many drug trials, 19 and less than 2% of pharmacokinetic (PK) studies carried out in the US involved pregnant women. 18 Safe and effective prescribing during pregnancy can only be achieved by performing drug trials on pregnant women, and guidelines have been published to advise how such studies can best be designed, conducted and governed. 1 While it is understandable that, for safety reasons, pregnant women are excluded from general drug trials, our findings show a marked paucity of drug trials to assess the efficacy and safety of drugs employed to treat common pregnancy conditions. Our analysis also shows that, of the active pregnancy drug trials identified, fewer than 4% had a PK component incorporated in the study design. From these data it would appear that the basis for pharmaceutical prescribing in pregnancy will not improve in the foreseeable future, and that-by necessity-most of the medications prescribed to pregnant women will be given either off-label or unlicensed, with inadequate information on dose, efficacy and safety in pregnancy.
Our findings are also consistent with a previous analysis of pharma-funded trials in pregnancy. 20 These authors concluded that the current pharma funding model fails to address the needs of the pregnant woman. There are currently no legislative or fiscal incentives for pharmaceutical companies to fund trials on pregnant women. 1, 17, 18 Our study (which included all clinical trials, not just commercially funded studies) shows that not only are trials of drugs in pregnancy remarkably under-represented in the trial registries (by about 50-fold, according to our comparative analysis), but that the proportion funded by the pharmaceutical industry is extremely low at only 7%; this figure is markedly lower than for other areas of medicine, where rates are typically 30-60%. Interestingly, the largest therapeutic area (analgesia and anaesthesia) had no pharma-funded studies, and neither did the PPH and autoimmune areas, or studies aimed at improving fetal health. Presumably this reflects the perception that the opportunity for profit in these areas is negligible. In this context, it is interesting to note that, although almost one-third of the medications included in the trials analysed in this study were being tested for new applications in pregnancy, only three drugs were actually novel pharmaceuticals not already approved and prescribed for other applications outside of pregnancy; a G-CSF agent designed to prevent miscarriage (UMIN000005830), an antioxytocic agent designed for tocolysis (NCT02326142), and a cardiovascular drug with potential applications in treating pre-eclampsia (NCT01566630).
Strengths and limitations
The strength of the present study lies in its novelty, its systematic and unbiased approach, global inclusivity and robust data filtering and analysis. However, there are also three main limitations. First, while we specifically included WHO approved clinical trial registries to ensure only relevant and high quality trials were included, this resulted in the non-inclusion of trials that were not encompassed by these registries. Several countries appeared to have no active trials over the 2013-2014 period, which is unlikely to be accurate. In particular, trials conducted in Russia and other 'Eastern bloc' countries have not been captured; based on sources listing the number of trials instigated in these countries in 2013 and 2014 (approximately 1500), we estimate that 15-20 additional pregnancy trials may have been omitted from our analysis, a relatively small inaccuracy. Secondly, the lack of consistent and effective search functions across each database entailed that identification of eligible trials and determination of areas of interest required individual assessment and judgment with respect to funding source, novelty and status. This may have introduced inaccuracies through human error. Finally, we were unable accurately to acquire data on recruitment success, adverse events or study closures without outcome; hence, a number of studies included in the analysis may have been never completed or abandoned due to recruitment difficulties, without this being recorded on the registry.
Interpretation
These data highlight a major problem in the medical care of pregnancy complications: investment in developing and testing new drugs for the purpose of treating pregnancyspecific conditions is virtually non-existent, so that almost all pharmaceutical progress in the treatment of pregnant women is reliant on the repurposing of existing medications. There are a significant number of pregnancy-specific complications that would benefit from the development of novel and targeted pharmaceuticals aimed at addressing placenta-specific targets and functions; our findings would indicate that this is either not happening or not progressing to the clinical trial stage. Even including the trials where existing drugs are 'repurposed', only 15 trials were identified with a focus on treating IUGR or placental/amniotic complications, indicating that these extremely important areas of need are not receiving the pharmacological attention they deserve.
We suggest that active encouragement and changes in the clinical trial regulatory landscape may be required to rectify this situation and increase the development and trialing of pregnancy-specific pharmaceuticals. Advocacy and political pressure from consumers, organisations and individuals involved in obstetric and maternal-fetal medicine is essential in order to raise awareness of the issue and create an impetus for change. In particular, two changes should take place to rectify this situation. First, pregnant women should not be excluded from evaluations of general drugs that could be of benefit to women in pregnancy; explicit attention should be paid to the evaluation of those drugs in pregnant women. Secondly, programs that develop and evaluate drug therapies specifically for pregnancy disorders, such as pre-eclampsia, preterm birth and growth restriction, need to be developed, encouraged and supported. Only by doing so, will we start to improve the pharmaceutical landscape that currently is detrimental to pregnant women and their offspring. A program analogous to the successful UK Medicines for Children Research Network (MCRN) might be a strategy worthy of exploration.
Conclusions
In conclusion, our study suggests that, despite the various international initiatives to encourage drug trials in pregnancy and improve transparency in pregnancy drug administration and safety, there is widespread and systemic under-researching of medication development and evaluation in pregnancy. Based on our findings, we believe there is little prospect in sight that new medications will be developed and evaluated for treating pregnancy complications. Unless there are appropriate policy changes and initiatives, women will continue to receive medications that have not been properly tested prior to administration in pregnancy and will maintain their regrettable status as 'drug orphans'.
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